null
ChEBI ID: 38060
| Member | Definition | Class |
|---|---|---|
| cyromazine | cyromazine |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 34 (21.38) | 18.7374 |
| 1990's | 24 (15.09) | 18.2507 |
| 2000's | 29 (18.24) | 29.6817 |
| 2010's | 53 (33.33) | 24.3611 |
| 2020's | 19 (11.95) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (1.18%) | 5.53% |
| Reviews | 1 (0.59%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 167 (98.24%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 61.6448 | 1 | 1 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 63.4715 | 2 | 2 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 8.7090 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.9224 | 2 | 2 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 0.0050 | 1 | 1 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 28.9240 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 48.9662 | 2 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 0.1949 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 1 | 1 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 28.4867 | 2 | 2 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 52.2018 | 2 | 2 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 38.1838 | 2 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 21.8211 | 2 | 2 |